Intellia Therapeutics Inc - Real-time stock metrics, market data, and comprehensive analysis
Fetching stock data...
Intellia Therapeutics, Inc. is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies.
No news available
Have a question or want to work together? Fill out the form below and we’ll get back to you as soon as possible.
